LAMEA Smart Inhalers Market Size, Share & Forecast by 2027

LAMEA Smart Inhalers Market Size, Share & Industry Trends Analysis Report By Product, By Disease Indication, By Distribution Channel, By Country and Growth Forecast, 2021 - 2027

Published Date: April-2022 | Number of Pages: 90 | Format: PDF | Report ID: KBV-17513

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Smart Inhalers Market, by Product
1.4.2 LAMEA Smart Inhalers Market, by Disease Indication
1.4.3 LAMEA Smart Inhalers Market, by Distribution Channel
1.4.4 LAMEA Smart Inhalers Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials

Chapter 4. LAMEA Smart Inhalers Market by Product
4.1 LAMEA Metered Dose Inhalers (MDI's) Market by Country
4.2 LAMEA Dry Powdered Inhalers (DPIs) Market by Country

Chapter 5. LAMEA Smart Inhalers Market by Disease Indication
5.1 LAMEA Asthma Market by Country
5.2 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country

Chapter 6. LAMEA Smart Inhalers Market by Distribution Channel
6.1 LAMEA Hospitals Pharmacies Market by Country
6.2 LAMEA Retail Pharmacies Market by Country
6.3 LAMEA Online Pharmacies Market by Country

Chapter 7. LAMEA Smart Inhalers Market by Country
7.1 Brazil Smart Inhalers Market
7.1.1 Brazil Smart Inhalers Market by Product
7.1.2 Brazil Smart Inhalers Market by Disease Indication
7.1.3 Brazil Smart Inhalers Market by Distribution Channel
7.2 Argentina Smart Inhalers Market
7.2.1 Argentina Smart Inhalers Market by Product
7.2.2 Argentina Smart Inhalers Market by Disease Indication
7.2.3 Argentina Smart Inhalers Market by Distribution Channel
7.3 UAE Smart Inhalers Market
7.3.1 UAE Smart Inhalers Market by Product
7.3.2 UAE Smart Inhalers Market by Disease Indication
7.3.3 UAE Smart Inhalers Market by Distribution Channel
7.4 Saudi Arabia Smart Inhalers Market
7.4.1 Saudi Arabia Smart Inhalers Market by Product
7.4.2 Saudi Arabia Smart Inhalers Market by Disease Indication
7.4.3 Saudi Arabia Smart Inhalers Market by Distribution Channel
7.5 South Africa Smart Inhalers Market
7.5.1 South Africa Smart Inhalers Market by Product
7.5.2 South Africa Smart Inhalers Market by Disease Indication
7.5.3 South Africa Smart Inhalers Market by Distribution Channel
7.6 Nigeria Smart Inhalers Market
7.6.1 Nigeria Smart Inhalers Market by Product
7.6.2 Nigeria Smart Inhalers Market by Disease Indication
7.6.3 Nigeria Smart Inhalers Market by Distribution Channel
7.7 Rest of LAMEA Smart Inhalers Market
7.7.1 Rest of LAMEA Smart Inhalers Market by Product
7.7.2 Rest of LAMEA Smart Inhalers Market by Disease Indication
7.7.3 Rest of LAMEA Smart Inhalers Market by Distribution Channel

Chapter 8. Company Profiles
8.1 Adherium Limited
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.1.5.2 Approvals and Trials:
8.2 GlaxoSmithKline PLC (GSK)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.3 Teva Pharmaceutical Industries Ltd.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.5 OPKO Health, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.6 Aptar Group, Inc. (Cohero Health Inc.)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Approvals and Trials:
8.8 ResMed, Inc. (Propeller Health)
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Cognita Labs, LLC
8.9.1 Company Overview
8.9.2 Recent strategies and developments:
8.9.2.1 Approvals and Trials:
8.10. Vectura Group plc (Philip Morris International, Inc.)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities